FDA Approves Portola Pharmaceuticals ’ Andexxa, First and Only Antidote for the Reversal of Factor Xa Inhibitors

SOUTH SAN FRANCISCO, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], the first and...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news